Bicara Therapeutics Inc. (BCAX)
| Market Cap | 1.40B +73.3% |
| Revenue (ttm) | n/a |
| Net Income | -157.32M |
| EPS | -2.80 |
| Shares Out | 65.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 495,657 |
| Open | 22.36 |
| Previous Close | 22.38 |
| Day's Range | 21.18 - 22.40 |
| 52-Week Range | 7.80 - 24.25 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 30.27 (+42.11%) |
| Earnings Date | May 11, 2026 |
About BCAX
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for BCAX stock is "Buy." The 12-month stock price target is $30.27, which is an increase of 42.11% from the latest price.
News
Bicara Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
Ficerafusp alfa, a bifunctional antibody targeting EGFR and TGF-beta, shows deep and durable responses in head and neck cancer, with a pivotal phase III trial focused on HPV-negative patients and top-line data expected mid-2025. The company is well-funded, planning for commercial launch, and expects to present new data at ASCO and in colorectal cancer later this year.
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wit...
Bicara Therapeutics price target raised to $37 from $36 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Bicara Therapeutics (BCAX) to $37 from $36 and keeps an Overweight rating on the shares. The first quarter was focused on continued…
Bicara Therapeutics price target raised to $18 from $16 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Bicara Therapeutics (BCAX) to $18 from $16 and keeps a Neutral rating on the shares. The firm updated its model following the…
Bicara Therapeutics reports Q1 EPS (93c), consensus (65c)
“The first quarter of 2026 reflects strong progress as we work to position ficerafusp alfa as the cornerstone of treatment in HPV-negative head and neck cancer. In addition to advancing…
Bicara Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw strong clinical and operational progress, with FICERA advancing in pivotal trials and new leadership supporting commercial readiness. Financial position was bolstered by an oversubscribed offering, extending cash runway into 2029.
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026
Bicara Therapeutics initiated with a Buy at Guggenheim
Guggenheim last night initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $42 price target With 12 months to the company’s first Phase 3 data for ficerafusp alfa…
Bicara Therapeutics initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $42 price target
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wit...
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients w...
Bicara Therapeutics management to meet with Citizens
Meeting to be held in New York on April 8 hosted by Citizens.
Bicara Therapeutics price target raised to $16 from $11 at Wells Fargo
Wells Fargo analyst Eva Fortea Verdejo raised the firm’s price target on Bicara Therapeutics (BCAX) to $16 from $11 and keeps an Equal Weight rating on the shares. The firm…
Bicara Therapeutics price target raised to $16 from $14 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Bicara Therapeutics (BCAX) to $16 from $14 and keeps a Neutral rating on the shares. Bicara Therapeutics reported Q4 and full-year results,…
Bicara Therapeutics Earnings Call Transcript: Q4 2025
Achieved key milestones with FDA breakthrough therapy designation and strong clinical data for ficerafusp alfa, advancing to phase III and securing $161.8M in new funding. Cash runway extends into 2029, supporting regulatory, commercial, and development initiatives.
Bicara Therapeutics reports Q4 EPS (68c), consensus (65c)
As of December 31, 2025, Bicara had cash, cash equivalents and marketable securities of $414.8M, compared to $489.7M in cash and cash equivalents as of December 31, 2024. “Bicara enters…
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loadi...
BofA starts Bicara Therapeutics with a Buy on head and neck cancer potential
As previously reported, BofA analyst Tazeen Ahmad initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $35 price target Bicara is developing ficerafusp alfa as “a potentially transfo...
Bicara Therapeutics initiated with a Buy at BofA
BofA initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $35 price target
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients w...
Bicara Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
The session highlighted strong clinical activity and durability for a bifunctional EGFR TGF-beta antibody in HPV-negative head and neck cancer, with a 21% complete response rate and robust safety profile. A pivotal phase III trial is underway, and commercial infrastructure is being built for a U.S. launch.
Bicara Therapeutics announces inducement grants
Bicara Therapeutics (BCAX) awarded an inducement grant on March 2, 2026 to one new employee under Bicara’s 2026 Inducement Plan as a material inducement to employment. The employee received a…
Bicara Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
FICERA, a bifunctional antibody targeting EGFR and TGF-beta, is showing strong efficacy and durability in HPV-negative head and neck cancer, with a pivotal trial progressing globally and FDA support for the 1,500 mg dose. Commercial launch is planned for 2028, with expansion into CRC and PDAC underway.
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients wi...
Bicara Therapeutics 7.175M share Spot Secondary priced at $16.00
Morgan Stanley, TD Cowen, BofA, Cantor Fitzgerald and Stifel acted as joint book running managers for the offering.